VOR Latest Headlines

Vor Bio spikes as J.P. Morgan starts at Overweight on lead asset

at seekingalpha.com (Tue, 9-Dec 10:53 AM)

Vor Biopharma’s Telitacicept: A Promising Buy Amidst Valuation Disconnect and Strategic Focus on Unmet Needs

at www.tipranks.com (Tue, 9-Dec 9:25 AM)

Vor Biopharma Approves Stock Option Repricing Plan

at www.tipranks.com (Tue, 9-Dec 8:17 AM)

Telitacicept Shows Consistent Late-Stage Success Across Multiple Autoimmune Diseases: Vor Bio Reports Q3 2025 Results

Market Chameleon (Fri, 14-Nov 8:48 AM)

Vor Bio Launches $100 Million Public Offering—A Strategic Step to Advance Phase 3 Clinical Trials

Market Chameleon (Tue, 11-Nov 9:10 AM)

Vor Bio Highlights Telitacicept's Statistically Significant Efficacy in Phase 3 Primary Sjögren’s Disease Trial

Market Chameleon (Tue, 14-Oct 8:24 AM)

Vor Bio Grants New Employee Options at $30.40 Per Share Under Nasdaq Rule 5635(c)(4)

Market Chameleon (Mon, 6-Oct 9:49 AM)